GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diaceutics PLC (FRA:7DC) » Definitions » Price-to-Free-Cash-Flow

Diaceutics (FRA:7DC) Price-to-Free-Cash-Flow : N/A (As of May. 23, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Diaceutics Price-to-Free-Cash-Flow?

As of today (2025-05-23), Diaceutics's share price is €1.60. Diaceutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.06. Hence, Diaceutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Diaceutics's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 9 years, Diaceutics's highest Price-to-Free-Cash-Flow Ratio was 386.67. The lowest was 258.33. And the median was 322.50.

FRA:7DC's Price-to-Free-Cash-Flow is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 16.15
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Diaceutics's Free Cash Flow per Share for the six months ended in Dec. 2024 was €-0.05. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-0.06.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 7.30% per year.

During the past 9 years, Diaceutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 18.60% per year. The lowest was -8.70% per year. And the median was 7.30% per year.


Diaceutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Diaceutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diaceutics Price-to-Free-Cash-Flow Chart

Diaceutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - - 251.67 - -

Diaceutics Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 251.67 - - - -

Competitive Comparison of Diaceutics's Price-to-Free-Cash-Flow

For the Health Information Services subindustry, Diaceutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diaceutics's Price-to-Free-Cash-Flow Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Diaceutics's Price-to-Free-Cash-Flow falls into.


;
;

Diaceutics Price-to-Free-Cash-Flow Calculation

Diaceutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.60/-0.057
=N/A

Diaceutics's Share Price of today is €1.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Diaceutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Diaceutics  (FRA:7DC) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Diaceutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Diaceutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Diaceutics Business Description

Traded in Other Exchanges
Address
Kings Hall Health and Wellbeing Park, Dataworks, First Floor, Building Two, Antrim, Belfast, GBR, BT9 6GW
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives.

Diaceutics Headlines

No Headlines